NCOA1, as the androgen receptor (AR) coactivator, was found to be involved in prostate cancer progression, while NCOA1 knockdown induced a significant decrease in migration and invasion through the upregulation of protein kinase D1 (PRKD1) [32]. Here, PRKD1 is linked to prostate carcinoma.